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Abstract 
The cellular response to hypoxia is vital for skeletal tissue development and 
regeneration. Numerous processes, including progenitor cell recruitment, proliferation 
and differentiation, are activated through the hypoxia pathway in a low oxygen pressure 
environment. Novel materials-based strategies designed to activate the hypoxia 
pathway are therefore of great interest for orthopaedic tissue engineering. 
Here resorbable bioactive glasses (BG) were designed to activate the hypoxia pathway 
by substitution of Co2+ for Ca2+ in the BG and substitution of Co2+ and Ca2+/+2Na+ for 
Si4+. This allowed for the controlled release of cobalt, whilst controlling BG bioactivity 
(apatite-forming ability). Two series of soda-lime-phosphosilicate glasses were 
manufactured with increasing concentrations of cobalt. Compositions were calculated to 
maintain constant network connectivity (2.13) by considering cobalt as an intermediate 
oxide in the first series, and as a network modifier in the second series. Mg2+ and Zn2+ 
were added to one of the Co2+-containing glasses to inhibit HCA formation since delay 
or inhibition of HCA formation is essential for the use of BG in soft tissues, as is the case 
of cartilage. 
Cobalt was present in both the silicate and phosphate phases of the BG. In addition, 
evidence was found for it playing a dual role in the silicate phase, acting as both an 
intermediate oxide and taking part in the network as well as being a network modifying 
oxide. Consistent with an intermediate oxide role, the presence of cobalt in the BG was 
shown to decrease ion release. HCA formation was delayed with cobalt additions. Mg2+ 
and Zn2+ further delayed HCA formation. 
Cobalt release was found to be proportional to cobalt content of the BGs enabling the 
controlled delivery of cobalt in therapeutic active doses. 
 
Introduction 
A major challenge in bone tissue engineering is the development of constructs that can 
both promote bone formation and stimulate the formation of new blood vessels 
(angiogenesis). In vivo, low oxygen pressure (hypoxia) plays a vital role in the 
development and regeneration of skeletal tissue.  Hypoxia activates a series of cellular 
processes through the hypoxia pathway1, including stem cell recruitment2, angiogenesis3 
and stem cell differentiation4-5. Under normoxic conditions, the hypoxia inducible factor 
1α (HIF-1α, the transcription factor responsible for the activation of the hypoxia pathway) 
is constitutively synthesized in the cytoplasm but immediately degraded via 
proteosomes. However, under hypoxic conditions, HIF-1α degradation is inhibited, and 
the stabilised transcription factor is translocated into the nucleus where it dimerizes with 
HIF-1β. The newly formed HIF-1 dimer then binds to hypoxia responsive elements 
(HRE) present in target genes and recruits coactivator/inhibitor proteins, leading to their 
altered transcription1.  
Activation of the hypoxic response can be essential for long bone formation6-9 and 
enhances fracture repair10. Under hypoxia osteoblasts increase expression of vascular 
endothelial growth factor (VEGF), an angiogenic growth factor central to the 
establishment and repair of blood vessel networks11. More recently, hypoxia has also 
been shown to stimulate the production of angiogenic factors by both mesenchymal 
stem cells (MSC)2 - progenitor cells already used commercially in cartilage tissue 
engineering12 - and by osteoblasts cultured in 3D constructs10. Currently one of the 
major problems in bone tissue engineering is the absence of a mature 
microvasculature5, 13. Mimicking hypoxia by stabilizing HIF-1α has therefore been 
suggested as an efficient way of regulating the expression of a large number of pro- and 
anti-angiogenic genes14. The HIF-1α pathway is also vital for cartilage development, 
homeostasis and regeneration. Oxygen and vascular gradients are of great importance 
during cartilage development15 and chondrocyte metabolism normally operates at low O2 
tension due to the avascularity of cartilage15-16. The hypoxia pathway is essential in 
enabling chondrocytes to adapt their metabolism to a low oxygen pressure 
environment15. Hypoxic conditions in vitro can help maintain cell phenotype in cultured 
primary chondrocytes, delaying the in vitro ageing (dedifferentiation) of these cells that 
occurs over time15. Materials capable of regulating the cellular hypoxia pathway 
therefore offer great potential in skeletal tissue regeneration. 
Cobalt ions have been used extensively to mimic a hypoxic environment in vitro, due to 
a well-established stabilising effect on HIF-1α11, 17-19. However, exposure to high and/or 
prolonged concentrations of these ions has been shown to cause cell toxicity in vitro and 
pathologies in vivo, most likely via activation of redox pathways. A controlled ion release 
system is therefore vital for any tissue engineering (TE) strategy involving delivery of 
cobalt. One possible vehicle is that of cobalt-doped bioactive glasses (Co2+ BG). The 
45S5 Bioglass®, a specific BG composition, is a soda-lime-phosphosilicate that does not 
become surrounded by fibrous tissue when implanted; instead it forms an intimate bond 
to bone20. Bioglass® has Federal Drug Administration (FDA) approval and is 
commercially available for several applications in hard tissue restoration, in products 
such as NovaBone®, NovaMin®, Perioglas® and Vitoss-BA® 21. Several modified versions 
of 45S5 have been reported and different ions, such as strontium, magnesium or zinc, 
have been added to the initial composition with the aim of improving bone bonding and 
regeneration22-24. 
In this study cobalt ions were incorporated into two series of bioactive glasses and the 
role of cobalt within the BG network investigated. Due to cobalt’s charge to size ratio, it 
can enter the silicate network, e.g. as [CoO4]
2- species, but it can also act as a 
higher coordination-number network modifier25. According to the Zachariasen’s rules26-27 
and Dietzel’s criterion28, cobalt may act as an intermediate oxide because of its relatively 
high charge to size ratio. If we consider Co (II), CN=4 which is equivalent to CoO4
2- 
species, the cobalt charge to size ratio is 0.49 (value calculated based on data from29), 
very similar to magnesium (0.45 if CN=6 and 0.52 if CN=4), that has been shown to play 
a dual role in the silicate network22. However, if we consider Co (II) but CN=8, in which 
the cobalt could be considered isostructural to calcium, the cobalt charge to size ratio is 
0.35 (value calculated based on data from29), characteristic of a network modifier. 
Therefore, cobalt can also act as a network modifier, replacing bridging oxygens (BOs) 
for non-bridging oxygens (NBOs) in a similar fashion to calcium. The role of cobalt in the 
glass network will determine the network connectivity (NC) and the BG properties, such 
as ion release rates and hydroxycarbonated apatite (HCA) formation, will be affected.  
Since one of the proposed applications for the hypoxia stimulating BG is in cartilage 
tissue engineering, zinc and magnesium ions were added to one of the BG compositions 
in order to decrease HCA formation30-32, which would be undesirable for soft tissue 
applications. These two ions have previously been used in TE for a number of different 
purposes, including as dopants in the production of hydroxycarbonated apatite 
ceramics32, incorporation into polymeric microspheres33 and also doping in bioactive 
glasses22, 24, 34-35. Magnesium can increase chondrocyte proliferation and 
redifferentiation36-37 and zinc is involved in bone metabolism38. Moreover, both 
magnesium and zinc can improve osteoblast adhesion to scaffolds39-40 and promote 
osteogenic differentiation35, 38, 41-42. 
 
Materials and methods: 
Preparation of bioactive glasses 
Two series of cobalt BGs were prepared by the melt-quench route. The network 
connectivity was calculated at 2.13 assuming either an intermediate oxide or network 
modifier role for Co2+ (Table 1). The BG compositions were designed using the inorganic 
polymer model of soda-lime-phosphosilicate glasses with the general formula of 
3SiO2.0.07P2O5.(1.4-X)CaO.1.6Na2O.XAO (A = Co, Mg or Zn)
43. Cobalt oxide was 
added to the glass composition in different concentrations to produce two different glass 
series: a charge balanced series (CB) and a non-charge balanced series (NonCB), 
based on Co2+ acting as an intermediate oxide and network modifying oxide, 
respectively. For the CB series, the BG composition was designed in order to maintain a 
fixed network connectivity, assuming Co2+ substituted for Si4+ in the glass network (as a 
intermediate oxide). Thus, each mole of SiO2 content was replaced by one mole of CoO 
and one mole of CaO. BGs with Co2+ contents of 0, 1, 2, and 4 mole % were prepared. 
In the NonCB series CoO was substituted for CaO, to give Co2+ contents of 0, 0.5, 1, 2, 
and 4 mole %. All other BG components were kept constant. MgO and ZnO were added 
to a 2% Co2+ BG from the NonCB series to achieve 2 and 4 mole %. Once the 
compositions were prepared they were transferred to a platinum-rhodium crucible and 
placed into the pre-heated furnace (1400ºC for 90 min) and the molten contents of the 
crucible were then quenched into deionised water. The granular glass frit was collected 
and dried in an oven at 100ºC. Finally, the glass frit was ground into a powder and 
sieved to obtain particles smaller than 38µm. Glass powders were stored in a desiccator 
until used.  
 
Differential scanning calorimetry (DSC) 
Differential Scanning Calorimetry (DSC) was carried out on 50 mg samples of BG (< 38 
µm particles) between 50 and 1050 ºC at a ramp rate of 10 ºC min-1. A Polymer 
Laboratories Thermal Sciences was used and Al2O3 was used as the reference. 
 
Magic-angle-spinning nuclear magnetic resonance (MAS-NMR) spectroscopy 
29Si and 31P MAS-NMR were used to analyze the BG samples using a Bruker DSX-200 
NMR spectrometer operating at Larmor frequencies of 39.77 and 81.9 MHz, 
respectively. Samples were packed into a 4 mm zirconia rotor and spun at the magic 
angle (54.74˚) to remove anisotropy effects. The 29Si and 31P MAS-NMR spectra of the 
glasses were recorded at spinning frequencies from 3 to 12 kHz using a Bloch decay 
pulse sequence for both silicon and phosphorus. The 29Si and 31P MAS-NMR samples 
were spun with a recycle delay time set to 2.0 s (although this was increased to 60.0 s if 
the glass species were not thought to be completely relaxed). All spectra were recorded 
at an ambient probe temperature with 29Si referenced relative to polydimethylsilane 
(PDMS) and 85% H3PO4 for 
31P. 
 
Evaluation of ion release profiles from bioactive glasses 
The prepared BG samples were incubated in Tris buffer (45 mg of glass per 50 cm-3 Tris 
buffer or cell culture media) at 37 ºC, in an orbital shaker at 120 rpm. At intervals, 5 cm-3 
samples were collected, centrifuged and filtered. Inductively-coupled plasma optical 
emission spectrometry (ICP-OES) was performed on the resulting solutions and the 
concentrations of ions (silicon, calcium, sodium, phosphorus and cobalt) were 
calculated, based on standard solutions. ICP was performed using a Thermo Scientific 
iCAP 6000 Series ICP Spectrometer. 
 
Evaluation of hydroxycarbonated apatite (HCA) formation on bioactive glasses 
To assess HCA formation, 75 mg of BG powder (particles < 38μm) was added to 50 cm3 
of simulated body fluid (SBF), prepared according to the method proposed by Kokubo44 
in conical flasks. The samples were placed in an incubator at 37 °C for 8 h, 16 h, 24 h, 7 
days, 14 days, 21 days and 28 days. At these time points, the powder was collected by 
filtering, sprayed with acetone and then air dried. The formation of apatite was 
characterized using a Genesis II Fourier transform infrared spectrometer, within a range 
of 600 to 1600 cm-1 and a resolution of 8 cm-1.  
 
Results and discussion: 
The hypoxia pathway activates cellular responses fundamental for normal tissue 
development and regeneration that might be vital for skeletal tissue engineering.  
To develop a BG with the ability to activate the cellular hypoxia response in cells, cobalt 
oxide was added to the BG compositions in different mole % (referred to as % from now 
on) concentrations (Table 1). X-ray diffraction (XRD) analysis verified that the BGs were 
amorphous and not crystalline, as evidenced by a lack of sharp peaks in the traces (data 
not shown). 
 
Effect of Co2+ addition on the BG structure and dissolution properties 
Differential scanning calorimetry (DSC) was performed to determine the glass transition 
temperature (Tg) of the BGs. This is the transition from a glass to a viscous liquid on 
heating and is seen in the DSC trace as a negative deviation from baseline. The effect 
of Co2+ addition on Tg was compared for both the charge balanced (CB) and non-charge 
balanced (NonCB) BG series (Fig. 1). In the CB series, Tg remained constant until 2% 
Co2+ addition and then increased slightly. However, in the NonCB series, Tg decreased 
with Co2+ addition in a concentration-dependent manner with ≤ 2% Co2+, then increased 
with 4% Co2+. In general, the lower the Tg the weaker the bonds in the BG and the more 
easily degradable in a physiological environment. So, according to the data presented 
above, the addition of Co2+ has no significant effect on the BG structure of the CB 
series. The network connectivity of these BGs is constant (Table 1) as enough modifier 
(Na+ and Ca2+) was added to the BG to charge balance any [CoO4]
2- species formed. 
The relaxation of the silicate part of the BG network, which is of constant polymerisation 
across the CB series, will dominate the signal in the DSC trace, therefore it follows that 
Tg does not change significantly. Alternatively two processes could be occurring 
resulting in no significant change in Tg, for example the creation of a weakly bonded 
cobalt complex species and also polymerisation of the silicate network. In contrast, as 
Co2+ is added to the NonCB series the BG structure initially becomes weaker and more 
easily disrupted. However at a Co2+ content of 4% the opposite seems to happen and Tg 
increases. Since in the NonCB series Tg decreases abruptly with the incorporation of a 
small percentage of Co2+ in the BG composition and Si-O bonds are expected to be 
stronger than the Co-O bonds, the DSC data suggests Co2+ is acting as an intermediate 
oxide, partially entering the silicate network. As Co2+ enters the network, Co-O-Si bonds 
replace the stronger Si-O-Si bonds and thus the BG structure becomes weaker and 
more easily disrupted. However, when more than 2% Co2+ is added to the BG 
composition, the effect of replacing a network modifier (Ca2+) with Co2+ seems to 
predominate. At higher concentrations, replacing Ca2+ with Co2+ increases the degree of 
polymerization of the silicate network again as more Co2+ acts as a modifier and less 
Co-O-Si bonds occur in the network and Tg increases. The BG structure becomes 
stronger and less easily disrupted. In the CB series the data in Fig. 1 showed Tg is 
constant until 2% Co2+ is reached, whereupon it slightly increases. This suggests that 
Co2+ is acting partially as an intermediate oxide as the excess Ca2+ and Na+ ions added 
to the BG are charge balancing the cobalt complexes and not depolymerising the silicate 
network. The DSC data there indicates that possibly Co2+ is taking part in the silicate 
network and acting as modifying oxide in the BG structure. This behavior would parallel 
the behavior of other divalent cations with similar ionic sizes, such as Mg2+ and Zn2+, 
that have also been previously reported to act as both intermediate oxides and network 
and network modifiers in the BGs22, 24. 
If Co2+ is initially acting partially as an intermediate oxide and taking part in the silicate 
network, when replacing Ca2+ for Co2+ in the NonCB series, this should induce a change 
in the silicate Q2 structure towards a Q3 structure. On formation of the [CoO4]
2- species 
additional network modifying cations are required to charge balance the 2- charge, 
hence the degree of polymerization of the silicate network will increase. This change in 
the network connectivity could influence the chemical shift in 29Si MAS-NMR 
spectroscopy. In addition, it is also possible that Co2+ may charge balance the 
orthophosphate (PO4)
3- units in the glass. 31P MAS-NMR could also be influenced by the 
presence of Co2+ in the phosphate phase of the BG. Therefore, in order to further 
elucidate the role(s) of Co2+ in the glass structure, 29Si and 31P MAS-NMR were 
performed (Fig. 2 and Fig. 3, respectively). 
The 29Si MAS-NMR spectra of the NonCB (Fig. 2a) and CB (Fig. 2b) series showed that 
the resonance was invarient ca. -80 ppm across the series and broadened out with the 
addition of Co2+. In both cases the linewidth increased with Co2+ addition (Fig. 2c) due to 
a paramagnetic effect of the unpaired electrons in the partially filled d-orbitals of the Co2+ 
ion. The Q3 shoulder characteristic of the silicate structure did not increase with addition 
of Co2+ to the BG. However, a correlation was found between the 29Si MAS-NMR peak 
position (Fig. 2d) and the network connectivity, NC1 parameter (Table 1). 
A shift downfield was observed in the CB series with the addition of Co2+. This may be 
due to either Co2+ entering the network as an intermediate oxide or Co2+ acting as a 
network modifier depolymerising the network. In the NonCB series, however, the 
position of the 29Si MAS-NMR peak remains constant throughout the series. The same 
happens with the NC1 parameter, which was constant in the NonCB series and 
decreases in the CB BGs. As this correlation is usually used to determine the structural 
changes and NC1 was calculated assuming Co2+ is a network modifier, this data is 
consistent with a network modifier role for Co2+. The 31P MAS-NMR spectra shows 
orthophosphate is present in the BG. The position of the 31P peak does not significantly 
change with Co2+ addition; however, both 29Si and 31P MAS-NMR spectra (Fig. 2 and 
Fig. 3) broaden out with the addition of Co2+, which indicates that the Co2+ could be 
evenly distributed over the network units. The effect of paramagnetic cations is very 
difficult to analyse using the same approach as for alkali earth or alkali cations. The 
paramagnetic cations have many unpaired electrons that can interact with the nuclei and 
produce a number of different effects on the NMR spectrum45-46, including a reduction in 
spin-lattice relaxation, T1, times and broadening of the resonance line. Whereas some 
reduction in  spin-lattice relaxation, T1,  time is beneficial, for obtaining improved signal-
to-noise ratios, line broadening is detrimental, especially in MAS-NMR spectra of BGs 
where the peaks are already broad due to the variation in bond angles and distances in 
a disordered glass structure. In our 29Si and 31P MAS-NMR spectra both effects were 
observed (Fig. 2 and Fig. 3), but only for the CB series and not for the NonCB series. 
This difference, however, is associated with the compositional design rather than the 
role of the Co2+ cation. From the DSC, 29Si and 31P MAS-NMR data, Co2+ therefore 
appears to play a dual role in the silicate network depending on its concentration. This is 
also known to be the case for other divalent cations such as Mg2+ and Zn2+ 22, 24 of 
similar ionic size. 
Ion release profiles of the BGs in Tris buffer were analysed by ICP-OES (Fig. 4). The ion 
release profiles of the BGs from the NonCB series (Fig. 4 a-d) were more significantly 
affected by the addition of Co2+ than those of the CB series (Fig. 4 e-h). In the CB series 
the amount of Si4+, Ca2+ and Na+ released were similar across all compositions. 
However, in the NonCB series the addition of Co2+ seemed to decrease the release 
rates of Si4+, Ca2+ and Na+ ions. Initial Si4+ release is faster in those BGs with a low to 
zero Co2+ content (Fig. 4a), suggesting the intermediate oxide effect of Co2+ is 
predominant in this case. Ca2+ and Na+ release significantly decreases with addition of 
Co2+ to the BG in a concentration-dependent manner (Fig. 4b and 4c). The decrease in 
Ca2+ release might be partly explained by the < 20% lower Ca2+ content of the Co2+ BGs.  
However, only 20% of the Ca2+ is replaced by Co2+ whereas the release of Ca2+ 
decreases by 50% in the NonCB4Co as compared to the 0Co. This alone cannot fully 
account for the difference. In the case of Na+, however, its lower release is only due to 
the effect of Co2+ in the BG network since its concentration is kept constant through out 
the NonCB series. 
If Co2+ is acting as an intermediate oxide, the decrease of the ion release rates is easily 
explained. In the NonCB series the decreased ion release rates are due to the 
replacement of a network modifier (Ca2+) by an intermediate oxide (Co2+), which 
increases the degree of polymerization of the silicate network. In the CB series, a 
network former (Si4+) is replaced by another ion with the same role (Co2+), so there is no 
major effect on ion release rates. The ion release profiles are therefore in agreement 
with DSC data and suggest Co2+ acts partially as an intermediate oxide. 
Ion release from BG was also followed over a four week time period (here only 
phosphate release is reported). Fig. 5 clearly shows that the phosphate concentrations 
in the buffer can be associated with the presence of Co2+ in the BG. In both the NonCB 
and the CB BG series (Fig. 5a and 5b, respectively), phosphate ions stay in solution for 
a longer time period with increasing concentrations of Co2+ in the BG. For example, in 
the case of 0Co BG of the NonCB series, the phosphate concentration in the buffer fell 
to zero after 24 h. However, with increasing concentrations of Co2+ in the BG, phosphate 
ions remained in solution for up to 15 days. This could be due to slower precipitation of 
the orthophosphate ions as HCA or amorphous calcium phosphates in the Co2+-
containing BGs. Si4+ concentrations in solution are approximately constant over time and 
they are similar between the different BGs, which suggests the differences in phosphate 
concentration are not due to different release rates from the BG as degradability 
seemed to be similar in all BGs based on Si4+ release. The more persistent solubility of 
the phosphate ions (i.e. longer induction time for apatite formation) can then be 
explained by the formation of more stable complexes between Co2+ and phosphate than 
those formed between Ca2+ and phosphate. The fact that cobalt has more valence 
electrons and is more electronegative than calcium could explain the higher stability of 
the cobalt phosphate complexes. It is also possible that Co2+ affects the nucleation of 
HCA crystals as Mg2+ does, since these two ions have similar charge to size ratios. The 
decrease in nucleation rate would then explain the persistence of phosphate ions in 
solution with Co2+ addition to the BGs. 
In both BG series controllable Co2+ release was achieved with the novel BGs through 
modification of the Co2+ content of the BGs (Fig. 6). Higher Co2+ release rates were 
expected in the CB BG series regardless of Co2+ role in the BG network. However, the 
data revealed the opposite, in agreement with the Tg values, which also decrease more 
rapidly in the NonCB BG series. More importantly, Co2+ are released within a biologically 
active concentration range. In vitro47-48 and in vivo49 studies indicate that the 
physiologically active concentration range is between 50-250 μM (3-15 ppm). 
Additionally, the Co2+-containing BGs were tested and shown to activate the hypoxia 
response in SaOs2 cells (G. Jell, M. M. Azevedo, A. Zapata, M. Woisetschlager, M. 
Stapountzi, R. Hill, M. M. Stevens, Hypoxia inducible factor (HIF) stabilizing bioactive 
glasses, manuscript under preparation). 
 
Effect of Mg2+ and Zn2+ addition on BG structure and dissolution properties 
Substitution of Mg2+ and Zn2+ for Ca2+ in the Co2+-containing BGs resulted in a decrease 
in Tg (Fig. 7). Mg
2+ and Zn2+ can have a dual role in the BG network22, 24, both acting as 
intermediate oxides. If they act like intermediate oxides, the presence of Si-O-M bonds 
(M being Mg2+ or Zn2+) weakens the BG network because the newly created bonds are 
significantly weaker than Si-O-Si bonds. This explains the observed drop in Tg. 
However, if Mg2+ and Zn2+ act as network modifiers, we would expect Tg to increase 
because their ionic radii are smaller than that of Ca2+. These results suggest that these 
two ions can enter the silicate network and act as intermediate oxides and are in 
agreement with data previously reported22, 24, 29, 50-51. 
29Si and 31P MAS-NMR were performed on the Mg2+- and Zn2+-containing BGs. A shift 
upfield of the silicon peak was observed with the addition of both Mg2+ and Zn2+ to the 
BG. However, the addition of each Mg2+ and Zn2+ separately did not result in any 
significant shift of the silicon peak (Fig. 8a). 31P MAS-NMR spectra suggested that the 
phosphate phase of the BG was not affected by the addition of Zn2+. In contrast, the 
phosphate peak shifted to a more positive region of the spectra upon Mg2+ addition to 
the BG (Fig. 8b). This indicates that Na+ increasingly associates with orthophosphate 
groups as Ca2+ is substituted for Mg2+, suggesting Mg2+ is entering the network as an 
intermediate oxide. The same effect has been previously reported to occur in a 
concentration dependent manner over a range of Ca2+ substitutions from 25-100%22, 51. 
 
In agreement with published data,30, 52-55 the dissolution study performed here 
demonstrated decreased Si4+, Ca2+, Na+ and Co2+ release with the addition of both Mg2+ 
and Zn2+ to the BGs (Fig. 9). This was clearly seen for Ca2+ and Na+ release (Fig. 9b 
and 9c), and the effect was more pronounced with Zn2+ than with Mg2+ (Fig. 9a and 9d). 
These results can be explained by the possibility that these two metals may also act as 
network modifiers. Since both Mg2+ and Zn2+ have smaller ionic radii than Ca2+, 
replacing Ca2+ with either of these ions should result in a denser network, causing the 
BGs to be less reactive. Furthermore, Mg-O and Zn-O bonds are stronger than Na-O 
and Ca-O bonds. On the contrary, if Mg2+ and Zn2+ were to act as intermediate oxides 
and take part in the silicate network, the BG would become weaker due to the formation 
of Si-O-M and M-O-M bonds and this would increase ion release rates. However, in this 
instance, a further consideration is that in this scenario Ca2+ – a network modifier – is 
replaced by an intermediate oxide, which could decrease the BGs dissolution rates due 
to a greater degree of polymerization of their network. If Mg2+ and Zn2+ replace Ca2+ as 
network modifiers, the glass structure will also be strengthened since the ionic radii of 
Mg2+ and Zn2+ are smaller than that of Ca2+. In this case, the BG network will be tighter 
and ion release rates will decrease. These findings corroborate previous work22, 24 and 
suggests these two ions can play a dual role acting to take part in the silicate network 
and acting to disrupt it.  
 
Bioactivity of and HCA formation on the bioactive glasses 
The ability of the BGs to form hydroxycarbonated apatite (HCA) according to the Kokubo 
protocol44 was studied. In this study the SBF test was used to assess the effect of Co2+, 
Mg2+ and Zn2+ addition to the glass on HCA formation, since HCA formation is 
undesirable if the BG is to be used in soft tissue tissue engineering (eg. cartilage tissue 
engineering). This test has been previously used to assess BG bioactivity or bone 
binding ability in vitro. The limits of the SBF test in definitively predicting HCA formation 
and in vivo behaviour however should be considered56.  
Fig. 10 shows the FTIR spectra of the different BGs from the NonCB series after 
incubation in SBF for 1, 2, 3 and 4 weeks. The peak at 570 cm-1 indicates the formation 
of an amorphous calcium phosphate layer. This peak splits into two peaks at 613 cm-1 
and 574 cm-1, thus indicating formation of an apatite crystalline phase57-58. After 1 week 
in SBF only the 0Co BG shows the presence of crystalline HCA (Fig. 10a). After 2 
weeks (Fig. 10b), however, in the FTIR spectra of all Co2+-containing NonCB BGs peaks 
at 613 cm-1 and 574 cm-1 are observed, indicating the formation of the HCA crystalline 
layer on these BGs. The spectra of the Mg2+-containing BGs and the NonCB2Co4Zn BG 
only present the crystalline HCA peaks at 613 cm-1 and 574 cm-1 after 3 and 4 weeks 
incubation in SBF, respectively (Figs. 10c and 10d, respectively). Therefore, the 
presence of Co2+, Mg2+ and Zn2+ in the BG significantly delays the formation of a HCA 
layer and this delaying effect is strongest with Mg2+ and Zn2+. This result is in agreement 
with the dissolution data discussed above, since cobalt addition to the BGs was shown 
to decrease ion release, an essential step for HCA formation. The effect with Mg2+ and 
Zn2+ was already expected, as these two ions have been previously shown to delay 
HCA formation (S. Watts, R. V. Law, R. Hill, The influence of magnesium on the 
bioactivity of bioactive glasses, manuscript under preparation and 24). Different 
mechanisms have been proposed to explain this effect. Some authors suggest Zn2+ can 
adopt a tetrahedral coordination and copolymerize with [SiO4] tetrahedra, inducing 
complexation of the silicate network, which will decrease ion dissolution and delay HCA 
formation52, 55. Other authors propose that the Mg2+ and Zn2+ ions can reduce the 
nucleation rate of apatite in solution and then bind to the surface of apatite crystals and 
delay the crystallization of amorphous apatite54, 59-62. Since Co2+ has similar properties 
and seems to behave as Mg2+ and Zn2+ in the silicate network, it is possible that it has 
the same effect on HCA crystallization. The fact that Zn2+ has a stronger effect than 
Mg2+ has been previously reported by Li et al. and is in agreement with our data59.  
 
Conclusion 
Novel hypoxia-mimicking BGs were successfully developed introducing different 
amounts of Co2+ ions in the BG network. Co2+ was shown to be present in both silicate 
and phosphate phases of the synthesized BGs. In the orthophosphate phase of the 
BGs, Co2+ seems to charge balance the orthophosphate groups. In the silicate phase of 
the BGs, however, Co2+ seems to play a dual role depending on the concentration at 
which Co2+ is present in the BG. As expected, addition of Co2+ to the BG was also 
shown to alter the BG properties. BG dissolution, ion release and HCA formation are 
delayed by inclusion of Co2+ in the BG in a concentration-dependent manner. 
As previously reported, Mg2+ and Zn2+ also have a dual role in the silicate network as 
both network formers and network modifiers. A delay in HCA formation was achieved 
upon the addition of these two cations. The addition of either Co2+, Mg2+, Zn2+ or a 
combination of all three prevents HCA formation, which is essential and very promising 
for the use of these BGs in TE of soft tissues such as cartilage. More importantly, the 
BGs presented here allow a tailorable and controlled release of Co2+ ions within a 
biologically active concentration range indicating that the materials hold great promise 
as new hypoxia-mimicking materials for regenerative medicine. 
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Table 1 Designed compositions of the BG used in this study in mole percentages. The 
two columns on the right indicate the Network Connectivity (NC) of each glass 
calculated according to the method described by Hill63-66. Network connectivity 1 (NC1) 
was calculated assuming Co2+ to be a network modifier and network connectivity 2 
(NC2) was calculated assuming Co2+ to be an intermediate oxide.  
 
Fig. 1 Glass transition temperature (Tg) as determined by DSC of NonCB and CB BG 
series as a function of mole percentage (M%) of Co2+ ions in the BG. 
 
Fig. 2 29Si NMR spectra of the Co2+-containing BGs. (a) 29Si NMR spectra of the NonCB 
BG series. (b) 29Si NMR spectra of the CB BG series. Spectra for NonCB BG series: (A) 
0Co; (B) NonCB0.5Co; (C) NonCB1Co; (D) NonCB2Co; (E) NonCB4Co. Spectra for CB 
BG series: (F) 0Co; (G) CB1Co; (H) CB2Co; (I) CB4Co). (c) Linewidth of the 29Si peaks 
as a function of Co2+ concentration in the BG for both NonCB and CB BG series. (d) 
Position of the 29Si peaks as a function of Co2+ concentration in the BG for both NonCB 
and CB BG series. 
 
Fig. 3 31P NMR spectra of the Co2+-containing BGs. (a) 31P NMR spectra of the NonCB 
BG series. (b) 31P NMR spectra of the CB BG series. Spectra for NonCB BG series: (A) 
0Co; (B) NonCB0.5Co; (C) NonCB1Co; (D) NonCB2Co; (E) NonCB4Co. Spectra for CB 
BG series: (F) 0Co; (G) CB1Co; (H) CB2Co; (I) CB4Co). (c) Linewidth of the 31P peaks 
as a function of Co2+ concentration in the BG for both NonCB and CB BG series. (d) 
Position of the 31P peaks as a function of Co2+ concentration in the BG for both NonCB 
and CB BG series. 
 
Fig. 4 Concentration of the different cations in Tris buffer as determined by ICP-OES as 
a function of time after incubation of BGs from both NonCB and CB BG series for up to 
4h. (a-d) NonCB BG series; (e-h) CB BG series; (a and e) Si4+ concentration; (b and f) 
Ca2+ concentration; (c and g) Na+ concentration; (d and h) Co2+ concentration. 
 
Fig. 5 Phosphate concentration in Tris buffer as determined by ICP-OES as a function 
of time after incubation of BGs from both NonCB and CB BG series for up to 28 days. 
(a) NonCB BG series; (b) CB BG series; (c) Mg2+- and Zn2+-containing BGs from the 
NonCB series. 
 
Fig. 6 Cobalt concentration in Tris buffer as determined by ICP-OES as a function of 
mole percentage (M%) of Co2+ after incubation of BGs from both NonCB and CB BG 
series for 4h. 
 
Fig.7 Glass transition temperature (Tg) as determined by DSC of Mg
2+- and Zn2+-
containing BGs from the NonCB BG series as a function of the mole percentage (M%) of 
both Mg2+ and Zn2+ ions in the BG. 
 
Fig. 8 29Si and 31P NMR spectra of the Mg2+- and Zn2+-containing BGs from the NonCB 
BG series. (a) 29Si NMR spectra, (b) 31P NMR spectra. Spectra: (A) 0Co; (B) 
NonCB2Co; (C) NonCB2Co4Zn; (D) NonCB2CoMgZn; (E) NonCB2Co4Mg. 
 
 
Fig. 9 Concentration of the different cations in Tris buffer as determined by ICP-OES as 
a function of time after incubation of the Mg2+- and Zn2+-containing BGs from NonCB BG 
series for up to 4h. (a) Si4+ concentration; (b) Ca2+ concentration; (c) Na+ concentration; 
(d) Co2+ concentration. 
 
Fig. 10 FTIR spectra of the BGs from the NonCB series after incubation in simulated 
body fluid (SBF) for up to 28 days. (a) FTIR spectra of the BGs after 7 days in SBF; (b) 
FTIR spectra of the BGs after 14 days in SBF; (c) FTIR spectra of the BGs after 21 days 
in SBF; (d) FTIR spectra of the BGs after 28 days in SBF. Spectra for NonCB BG series: 
(A) 0Co; (B) NonCB1Co; (C) NonCB2Co; (D) NonCB4Co; (E) NonCB2Co4Mg; (F) 
NonCB2CoMgZn; (G) NonCB2Co4Zn. 
 
  
 
Series BGs SiO2 P2O5 CaO Na2O CoO ZnO MgO NC1 NC2 
 0Co 49.46 1.07 23.08 26.38    2.13 2.13 
N
o
n
C
B
 
NonCB0.5Co 49.46 1.07 22.58 26.38 0.50   2.13  2.192.1  2.19   2.19 
NonCB1Co 49.46 1.07 22.08 26.38 1.00   2.13 2.25 
NonCB2Co 49.46 1.07 21.08 26.38 2.00   2.13 2.36 
NonCB4Co 49.46 1.07 19.08 26.38 4.00   2.13 2.57 
NonCB2Co4Mg 49.46 1.07 17.08 26.38 2.00  4.00 1.97 2.62 
NonCB2CoMgZn 49.46 1.07 17.08 26.38 2.00 2.00 2.00 1.97 2.62 
NonCB2Co4Zn 49.46 1.07 17.08 26.38 2.00 4.00  1.97 2.62 
C
B
 
CB1Co 48.94 1.08 24.32 26.64 1.01   2.01 2.13 
CB2Co 48.40 1.09 25.58 26.90 2.04   1.88 2.13 
CB4Co 47.27 1.11 28.16 27.43 4.16   1.61 2.13 
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